MICROBIOTA COMPOSITION, HOST GENE-EXPRESSION ANDINFLAMMATORY BOWEL DISEASES

Background and Aim : Dysbiosis emerges as a key factor in IBD pathogenesis. The aim of thepresent study is to profile changes in the gut microbiome and transcriptome in patients withinflammatory bowel disease and to correlate the potential changes with the administration of anti-TNF agent Infliximab in order to investigate their potential to predict patient response to anti-TNFtherapyMethods : Mucosal biopsy samples from IBD patients and nine healthy controls (HC) wereexamined for differences in microbiota composition (۱۶S rRNA gene sequencing) and mucosalgene expression (RT-qPCR) at baseline and upon completion of IFX treatment, accordingly, viaan in silico pipeline.Results : Significant differences in microbiota composition were found between the IBD and HCgroups. Several bacterial genera, which were found only in IBD patients and not HC, had theirpopulations dramatically reduced after anti-TNF treatment regardless of response. Alpha and betadiversity metrics showed significant differences between our study groups. Correlation analysisrevealed six microbial genera associated with differential expression of inflammation-associatedgenes in IFX treatment responders at baseline. This study shows that IFX treatment has a notableimpact on both the gut microbial composition and the inflamed tissue transcriptome in IBDpatients.Conclusion : Our study reveal enterotypes that correlate with transcriptome changes and helpdifferentiate IFX responders versus non-responders at baseline, suggesting that, in combination,these signatures can be an effective tool to predict anti-TNF response.

کلیدواژه ها:

microbiota ، IBD ، genetics